

Phase II study of subcutaneous and intravenous GI-102, innovative targeted cytokine, for patients with metastatic melanoma (KEYNOTE-G08)



ONCOLOGY		Phase 2
Product Type	Bispecific fusion protein	
Indication	Advanced or metastatic melanoma	
Target	CD8+ T/NK cell	
MoA(Mechanism of Action)	GI-102 : CD80/IL-2v3 bispecific fusion protein • CD80 : Tumor / immune cell targeting, Functional blockade of Treg activity • IL-2v3 : Selective binding to IL-2Rβγ, but not to IL-2Rα	
Competitiveness	• Demonstrating superior monotherapy efficacy and significantly greater expansion of CD8+ T / NK cells compared to IL-2 agents under development • Available for both intravenous and subcutaneous injection • Synergistic anti-cancer activity with immunotherapy, ADC and/or CAR-T therapy, providing great safety and tolerability	
Development Stage	Clinical (Phase 2)	
Route of Administration	Intravenous Subcutaneous	